Does the FDA approve Gilead's anito-cel for multiple myeloma?
Will the FDA approve the Biologics License Application for anitocabtagene autoleucel (anito-cel) for relapsed/refractory multiple myeloma by its December 23, 2026 PDUFA target action date, rather than issuing a Complete Response Letter or missing that date?
No public approval-probability estimate exists yet; informal analyst commentary leans toward approval given the late-line setting and an accepted BLA with no reported clinical hold
Bulls note that approval in a late-line, high-unmet-need multiple myeloma setting with an accepted BLA and no reported safety flags is, in one analyst's words, close to 'a no-brainer,' consistent with the high approval base rate for CAR-T products in this indication once a BLA is accepted. Skeptics point out the FDA's choice of standard rather than priority review as a signal the agency saw the data package as less compelling than some competing late-line filings, and note that Capricor's and other sponsors' CRLs this year show accepted BLAs do not guarantee approval on the published date.
Resolves Dec 23, 2026 · FDA PDUFA target action date for the anito-cel BLA
Gilead acquired Arcellx for an implied $7.8 billion equity value in a deal announced Feb 23, 2026, explicitly to fold anito-cel into its oncology pipeline; the agreement includes a contingent value right that pays out if cumulative global anito-cel sales reach $6.0 billion by the end of 2029, and Gilead has said the deal should be accretive to earnings per share from 2028 once the product is approved. The FDA accepted the BLA for relapsed/refractory multiple myeloma, supported by Phase 1/2 iMMagine-1 data, and set a December 23, 2026 target action date; one trade publication reads the date as implying standard rather than priority review. The product would compete directly with Legend Biotech/J&J's Carvykti and Bristol-Myers Squibb's Abecma, both already-approved BCMA-targeted CAR-T therapies in the same late-line multiple myeloma setting, with Carvykti already a commercial blockbuster.
The FDA either approves the BLA by its stated target action date or it doesn't (a Complete Response Letter, a delay, or an extended review all count as no) — a discrete regulatory decision due on a published date.
Researched Oct 30, 2026 · tracked since Oct 30, 2026
What do you think?
Take a side
FDA approves anito-cel on timethis is “yes”
The BLA was accepted on the strength of Phase 1/2 iMMagine-1 data in a late-line, high-unmet-need multiple myeloma setting with no reported clinical hold, and Gilead has already guided to earnings accretion 'upon FDA approval' — a setup several analysts read as a high-probability approval.
Worth knowing: This filing rests on Phase 1/2 data rather than a larger randomized Phase 3, and the FDA's apparent choice of standard review (rather than priority review) is a real signal worth weighing against the bullish read.
FDA delays or rejects anito-cel
A standard-review (not priority) designation suggests the FDA saw the data package as less compelling than top-tier late-line filings, the clinical support is still Phase 1/2 rather than Phase 3, and this year has already shown several sponsors miss PDUFA dates or receive CRLs despite accepted BLAs.
Worth knowing: Carvykti's own commercial success shows the FDA bar for BCMA-targeted CAR-T therapies in this setting is already cleared once — don't read generic late-line-oncology caution as a strong signal against this specific, already-accepted filing.
4 sources, leaning both ways
- mixedBioSpace — Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celChecked Oct 30: primary deal terms, CVR structure, and Gilead's own framing of the accretion timeline conditional on approval.
- mixedSEC — Arcellx, Inc. Form 10-K FY2025Checked Oct 30: primary source confirming the Dec 23, 2026 PDUFA target action date.
- yesOncology Pipeline — Gilead buys Arcellx before it's over the finish lineChecked Oct 30: frames approval in this late-line setting as highly likely given the clinical and regulatory posture.
- mixedGeneOnline — Gilead Acquires Arcellx for $7.8B to Advance Anito-cel in Multiple MyelomaChecked Oct 30: notes Legend/J&J's Carvykti as the commercial benchmark anito-cel would be measured against.